Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I trial of OMS 721 in volunteers: safety, tolerability, pharmacokinetics and pharmacodynamics.

Next Previous
X
Search
Trial Profile

Phase I trial of OMS 721 in volunteers: safety, tolerability, pharmacokinetics and pharmacodynamics.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 05 Mar 2014

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Narsoplimab (Primary) ; Narsoplimab (Primary)
  • Indications Haemolytic uraemic syndrome; Thrombosis
  • Focus Adverse reactions
  • Sponsors Omeros Corporation

    • Most Recent Events

    • 04 Mar 2014 Status changed from active, no longer recruiting to completed based on information in an Omeros Corporation media release. The company has submitted an IND for the phase II trial based on final data from this trial.
    • 04 Mar 2014 This study was conducted in the Netherlands under a Clinical Trial Application, according to an Omeros Corporation media release.
    • 03 Feb 2014 Top-line results reported in an Omeros Corporation media release following completion of dosing.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top